Loading
POU2F2 (POU domain, class 2, transcription factor 2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma and Diffuse large B-cell lymphoma.
Transcription factor that specifically binds to the octamer motif (5'-ATTTGCAT-3'). Regulates IL6 expression in B cells with POU2AF1. Regulates transcription in a number of tissues in addition to activating immunoglobulin gene expression.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. IntOGen calls it a driver in 4 cohorts (3 activating, 1 loss-of-function), covering Diffuse Large B-Cell Lymphoma, NOS, Malignant Lymphoma, Non-Hodgkin Lymphoma.
In plain words · POU2F2 (POU domain, class 2, transcription factor 2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma and Diffuse large B-cell lymphoma.
POU2F2 (POU domain, class 2, transcription factor 2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma and Diffuse large B-cell lymphoma.
Transcription factor that specifically binds to the octamer motif (5'-ATTTGCAT-3'). Regulates IL6 expression in B cells with POU2AF1.
No product in this corpus aims at POU2F2 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA POU2F2: RNA tissue enriched (lymphoid tissue 47 nTPM); high antibody staining in 2 normal tissues; highest cancer staining lymphoma (3 of 12 high). Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Lymphoma); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt P09086; CIViC gene POU2F2; IntOGen POU2F2; Human Protein Atlas POU2F2 tissue; Open Targets ENSG00000028277 associations
First described 1988. Earliest sequence paper UniProt cites for the protein: Clerc R.G. et al, Genes Dev, 1988, "The B-cell-specific Oct-2 protein contains POU box- and homeo box-type domains". Source.
Sources: HGNC HGNC:9213 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P09086 (protein name, function text, keywords and locations (REST API)); CIViC gene POU2F2 (1 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma (GraphQL API, CC0)); Open Targets ENSG00000028277 (per-cancer scores at or above 0.5: non-Hodgkin lymphoma 0.51 (GraphQL API, CC0)); IntOGen POU2F2 (driver in 4 cohorts (Act 3, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Transcription factor that specifically binds to the octamer motif (5'-ATTTGCAT-3'). Regulates IL6 expression in B cells with POU2AF1. Regulates transcription in a number of tissues in addition to activating immunoglobulin gene expression. Modulates transcription transactivation by NR3C1, AR and PGR. Activates the U2 small nuclear RNA (snRNA) promoter. Location: Cytoplasm; Nucleus (UniProt). Locus 19q13.2 (HGNC).
RNA: tissue enriched (lymphoid tissue 47 nTPM), detected in many normal tissues.
Medium: Appendix, Colon, Lymph node, Rectum.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"POU2F2" OR ABSTRACT:"POU2F2" OR TITLE:"POU class 2 homeobox 2" OR ABSTRACT:"POU class 2 homeobox 2" OR TITLE:"POU domain, class 2, transcription factor 2" OR ABSTRACT:"POU domain, class 2, transcription factor 2" OR TITLE:"OCT2" OR ABSTRACT:"OCT2" OR TITLE:"OTF2" OR ABSTRACT:"OTF2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about POU2F2, not a curated reading list.